Company Profile
KYORIN Pharmaceutical Co., Ltd., through its subsidiaries researches and develops, manufactures, and sells ethical and generic drugs in Japan and globally. The company offers Flutiform, a drug for the treatment of asthma.
Its portfolio also includes Lyfuna for cough treatment, Desalex, an antiallergic agent, Beova, and Uritos KYORIN therapeutic agents for overactive bladder, Lasvic, a quinolone synthetic antibacterial agent, Pentasa, a remedy for ulcerative colitis/Crohn's disease, Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents, and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug
Mucodyne, a mucoregulating drug. Its portfolio also includes GeneSoC, a real-time PCR system, Rubysta, a disinfectant cleaner, Milton, a disinfectant, over-the-counter drugs, and prescription medicines and quasi-drugs, and diagnostics business. Additionally, it offers subcontracted drug manufacturing services.
It has development and commercialization agreement with Hyfe Inc. for digital therapeutics (DTx) for chronic cough. Founded in 1923, The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical is headquartered in Tokyo, Japan.